Drug pricing white paper allays pharma patent fears, but innovators should remain vigilant

A recent report from the US president’s executive office on reducing drug prices makes reassuring reading for innovators concerned about the future of pharmaceutical patents under the Trump administration. In contrast to comments previously made by…

Unlock unlimited access to all IAM content